Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:54 PM
Ignite Modification Date:
2025-12-24 @ 4:54 PM
NCT ID:
NCT00817050
Eligibility Criteria:
Inclusion Criteria:
* Subject must have been 18-65 years of age, of either sex and any race.
* Subject must have had symptomatic allergic rhinitis with a total nasal symptom (congestion, rhinorrhea, sneezing, itching) severity score of \<6 but \>2; congestion must have been \<2.
* Subject must have been free of any clinically significant disease (other than allergic rhinitis) that would interfere with study evaluations.
* Subject must have understood and been able to adhere to the dosing and visit schedule.
Exclusion Criteria:
* Subject had used any investigational product within 30 days prior to enrollment.
* Subject was in a situation or condition that, in the opinion of the investigator, may have interfered with optimal participation in the study.
* Subject was participating in any other clinical study(ies).
* Subject was using any nasal lavage fluid or spray.
* Subject was using any perfume during the study day.
* Subject was using any oral rinse during the study day.
* Subject had used topical or oral nasal decongestants in the past 1 week.
* Subject had used a nasal corticosteroid in the previous 2 weeks.
* Subject had anosmia or ageusia (absence of the sense of smell or taste).
* Subject had been using medications which are associated with anosmia or ageusia in the 2 weeks prior to testing.
* Subject had a respiratory infection in the 2 weeks prior to testing.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT00817050
Study Brief:
Protocol Section:
NCT00817050